Camurus (CAMR.F) Stock Overview

A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. More details

CAMR.F fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	6/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 53.6% below our estimate of its fair value

Earnings are forecast to grow 35.24% per year

Analysts in good agreement that stock price will rise by 37.4%

Risk Analysis

Shares are highly illiquid

CAMR.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW425,651 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

425,651 investors already sharing narratives

View all narratives

Camurus AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Camurus
Historical stock prices
Current Share Price	SEK 61.75
52 Week High	SEK 71.00
52 Week Low	SEK 54.00
Beta	0.51
1 Month Change	-3.52%
3 Month Change	14.35%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	300.34%

Recent updates

Shareholder Returns

	CAMR.F	US Pharmaceuticals	US Market
7D	0%	1.7%	0.5%
1Y	n/a	47.1%	12.0%

Return vs Industry: Insufficient data to determine how CAMR.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CAMR.F performed against the US Market.

Price Volatility

Is CAMR.F's price volatile compared to industry and market?
CAMR.F volatility
CAMR.F Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	8.4%
Market Average Movement	6.8%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.9%

Stable Share Price: CAMR.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CAMR.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1991	316	Fredrik Tiberg	www.camurus.com

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud’s phenomenon.

Camurus AB (publ) Fundamentals Summary

How do Camurus's earnings and revenue compare to its market cap?
CAMR.F fundamental statistics
Market cap	US$3.49b
Earnings (TTM)	US$68.90m
Revenue (TTM)	US$230.28m

50.6x

P/E Ratio

15.1x

P/S Ratio

Is CAMR.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAMR.F income statement (TTM)
Revenue	SEK 2.27b
Cost of Revenue	SEK 157.01m
Gross Profit	SEK 2.11b
Other Expenses	SEK 1.43b
Earnings	SEK 678.17m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

Nov 05, 2026

Earnings per share (EPS)	11.40
Gross Margin	93.07%
Net Profit Margin	29.92%
Debt/Equity Ratio	0%

How did CAMR.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/17 03:03
End of Day Share Price	2026/09/01 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Camurus AB (publ) is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Gonzalo Artiach Castanon	Danske Bank
Kristofer Liljeberg-Svensson	DNB Carnegie

Camurus (CAMR.F) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Camurus AB (publ) Competitors

Indivior Pharmaceuticals

Organon

Harmony Biosciences Holdings

Amneal Pharmaceuticals

Price History & Performance

Recent News & Updates

Camurus AB (publ), Annual General Meeting, May 13, 2027

Camurus NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by US FDA

Camurus AB (Publ) Reaffirms Earnings Guidance for 2026

Camurus Provides Regulatory Update on the Us Nda for Cam2029 Oclaiz in Acromegaly

Camurus Appoints Jane Buus Laursen as Chief Corporate Development Officer, Effective March 23, 2026

Camurus AB (Publ) Provides Earnings Guidance for the Year 2026

Recent updates

Camurus AB (publ), Annual General Meeting, May 13, 2027

Camurus NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by US FDA

Camurus AB (Publ) Reaffirms Earnings Guidance for 2026

Camurus Provides Regulatory Update on the Us Nda for Cam2029 Oclaiz in Acromegaly

Camurus Appoints Jane Buus Laursen as Chief Corporate Development Officer, Effective March 23, 2026

Camurus AB (Publ) Provides Earnings Guidance for the Year 2026

Camurus AB (publ) Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

Camurus AB (publ) to Report Fiscal Year 2025 Final Results on Apr 29, 2026

Camurus AB (publ), Annual General Meeting, May 28, 2026

Camurus Reports Positive Topline Results for CAM2056, Semaglutide Monthly Depot

Camurus AB (Publ) Revises Earnings Guidance for the Year 2025

Camurus AB (publ) to Report Fiscal Year 2025 Results on Feb 12, 2026

Camurus Launches Long-Acting Oczyesa for the Treatment of Acromegaly

Camurus Announces Approval of Oczyesa for the Treatment of Acromegaly in the UK

Camurus' Oczyesa Receives Marketing Authorization for Treatment of Acromegaly in the EU

Camurus Announces Topline Results from the 12-Month, Randomized, Double-Blind, Placebo-Controlled POSITANO Phase 2b Study

Camurus AB (publ) (OM:CAMX) commences an Equity Buyback Plan for 240,000 shares, representing 0.41% of its issued share capital, under the authorization approved on May 27, 2025.

Camurus AB (Publ) Announces Jon Garay Alonso to Leave as Chief Financial Officer

Camurus AB (Publ) Provides Earnings Guidance for the Year 2025

Camurus AB (Publ) Revises Earnings Guidance for the Year 2024

Camurus AB (publ), Annual General Meeting, May 27, 2025

Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025

Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Camurus AB (Publ) Announces Board Resignations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Camurus AB (Publ) Elects Erika Söderberg Johnsson as Board Member

Camurus AB (Publ) Provides Earnings Guidance for the Year 2023